Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Copaxone Sales, Lower Charges Lift Teva First Quarter Profit

By Pharmaceutical Processing | May 4, 2010

NEW YORK (AP) — Teva Pharmaceutical Industries Ltd. said today its profit climbed 58 percent in the first quarter because of decreased buyout costs and better sales of its multiple sclerosis drug Copaxone.

The world’s largest maker of generic drugs said its profit rose to $713 million, or 79 cents per share, from $451 million, or 51 cents per share. Excluding one-time items, Teva said it earned 91 cents per share. Revenue grew 16 percent, to $3.65 billion from $3.15 billion.

Teva’s one-time costs included $130 million in amortization of purchased assets, legal settlements, and acquisitions costs. The company also posted a one-time tax benefit.

Analysts expected profit of 89 cents per share and $3.7 billion in revenue, according to a Thomson Reuters survey. Analyst estimates usually leave out one-time items.

The Israeli company said sales of Copaxone rose 28 percent to $796 million. It said North American sales grew 20 percent to $2.31 billion, and European sales were up 10 percent to $812 million. Sales in other regions increased 10 percent to $532 million.

Teva credited its North American results to sales of a generic version of the Parkinson’s disease drug Mirapex that was launched during the quarter, along with strong sales of its versions of Adderall XR for attention deficit hyperactivity disorder, the child asthma medication Pulmicort, Accutane for acne, and the colon cancer drug Eloxatin.

European sales were boosted by sales of Copaxone and the Parkinson’s disease drug Azilect. The company said its other international sales rose because of better sales in Russia.

Teva moved to further boost its overseas sales during the quarter. In March, it agreed to guy German generic drug maker Ratiopharm for about $5 billion.

In the first quarter of 2009, Teva took a series of one-time charges that totaled 20 cents per share. The largest was a $220 million inventory charge related to its acquisition of Barr Pharmaceuticals.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE